Ποια είναι η τιμή για GBS Inc. (GBS)

Η τιμή για GBS Inc. (GBS) είναι $0.4732

Ποια είναι η κεφαλαιοποίηση αγοράς για GBS Inc. (GBS)

Η κεφαλαιοποίηση αγοράς για GBS Inc. (GBS) είναι $7.05M

GBS Inc. (GBS) Τιμή και Κεφαλαιοποίηση Αγοράς

Operating across North America and the Asia-Pacific region, GBS Inc. specializes in biosensor diagnostic technology. Its key product is the Saliva Glucose Biosensor, an innovative organic thin-film transistor designed for diabetes management that quantifies glucose levels directly from saliva. The company is also actively advancing a SARS-CoV-2 Biosensor, intended as a supplementary diagnostic tool to existing RNA virus detection tests, and is constructing a broad biosensor platform covering diagnostic modalities such as biochemistry, immunology, tumor markers, hormones, and nucleic acids. GBS Inc. maintains a research agreement with the Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic solutions. Founded in 2016 and headquartered in New York, New York, the company adopted its current name, GBS Inc., in September 2019, having previously operated as Glucose Biosensor Systems (Greater China) Holdings, Inc. It operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Η τιμή για GBS	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$366,131 $7.05M	NVDA	$5.452T	+77,373,417.78%
$301,537 $7.05M	AAPL	$4.490T	+63,722,769.37%
$279,535 $7.05M	GOOG	$4.162T	+59,073,246.83%
$246,892 $7.05M	MSFT	$3.676T	+52,174,963.85%
$190,259 $7.05M	AMZN	$2.833T	+40,206,758.40%

Η τιμή για GBS

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$366,131 $7.05M